



**DATE: JANUARY 24, 2020**

**SUBJECT: AEVI GENOMIC MEDICINE, INC. – ANTICIPATED ADJUSTMENT  
OPTION SYMBOL: GNMX  
NEW SYMBOL: CERC1  
DATE: ???**

**Contract Adjustment**

**DATE:** Effective the opening of the business day after the merger is consummated. Contract adjustment is anticipated to occur in the first quarter 2020.

**OPTION SYMBOL:** GNMX changes to CERC1

**STRIKE DIVISOR:** 1

**CONTRACTS MULTIPLIER:** 1

**NEW MULTIPLIER:** 100 (e.g., a premium of 1.50 yields \$150; a strike of 2.50 yields \$250.00)

**NEW DELIVERABLE PER CONTRACT:**

- 1) A number of Cerecor Inc. (CERC) Common Shares based on an exchange ratio formula set forth in the Merger Agreement as described in the GNMX/CERC Proxy Statement/Prospectus dated December 31, 2019 (“Proxy”), x 100
- 2) Cash in lieu of fractional CERC shares, if any

**Note: The GNMX option deliverable will not be adjusted to include non-transferable Contingent Value Rights.**

**CUSIP:** CERC: 15671L109

**DELAYED SETTLEMENT**

OCC will delay settlement of the CERC component and the cash portion of the CERC1 deliverable until the final exchange ratio and cash in lieu of fractional CERC share amount, if any, are determined. Upon determination of the final exchange ratio and the cash in lieu amount, OCC will require Put exercisers and Call assignees to deliver the appropriate number of CERC shares and appropriate cash amount

**BACKGROUND**

On February 3, 2020, Shareholders of Aevi Genomic Medicine, Inc. (GNMX) will vote concerning the proposed merger with Cerecor Inc. (CERC). If the merger is approved and consummated, each existing

GNMX Common Share will be converted into the right to receive a number of CERC Common Shares based on an exchange ratio formula set forth in the Merger Agreement as described in the Proxy plus one non-transferable Contingent Value Right (“CVR”). Cash will be paid in lieu of fractional CERC shares, if any.

**Note:** The Contingent Value Rights represent a non-transferable contractual right to receive an additional payment. The adjusted CERC1 option deliverable will **not** include the non-transferable CVRs.

**EXERCISE CONSIDERATION** – GNMX options will not call for the delivery of the CVRs. Call option holders who wish to receive the CVRs, should exercise their options in sufficient time in advance of the contract adjustment. In all cases, it is the sole responsibility of persons holding call options seeking to receive the underlying securities to determine when to exercise their options.

### **DISCLAIMER**

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, call Investor Services at 1-888-678-4667 or email [investorservices@theocc.com](mailto:investorservices@theocc.com). Clearing Members may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email [memberservices@theocc.com](mailto:memberservices@theocc.com).